Table 2.
Summary of murine cell lines capable of orthotopic tumor formation
| Cell Line | Genotype | Sex | Treatment | Primary tumor size (mm) | Priamary tumor age | P1 time | P2 time | P3 time | P4 time | Total time in vivo | Time in culture | Time in orthotopic | Total time in vitro | Total Time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| X577 |
KrasG12D Smad4 fl/+ |
M | 2 ul 1010 CMV-Cre | 9 | 184 | 179 | 52 | 35 | 26 | 476 | 23 | 10 | 33 | 509 |
| X911 |
KrasG12D Tgfbr2fl/fl |
M | 2 ul 1010 SPC-Cre | 12 | 202 | 99 | 49 | 350 | 26 | 27 | 53 | 403 | ||
| E889 |
KrasG12D Map3K7fl/fl ROSAmTmG |
M | 2 ul 109 CMV-Cre | 3 | 180 | 184 | 54 | 418 | 45 | 45 | 90 | 508 | ||
| X381 |
KrasG12D Pten fl/+.p53fl/+ ROSAmTmG |
M | 2 ul 1010 SPC-Cre | 1–3 | 134 | 135 | 25 | 24 | 318 | 29 | 27 | 56 | 374 | |
| Y856 | R26StopFLP110*fl/+ p53fl/+ | F | 2 ul 1010 CMV-Cre | 6 | 78 | 81 | 159 | 125 | 24 | 149 | 308 | |||
| Y143 | C57BL/6 | F | 30ul 5 × 106 Ad-EA | 3–5 | 99 | 203 | 46 | 348 | 53 | 25 | 78 | 426 |
All times are in days